#1

In a landmark study that challenges several prevailing theories of longevity science, researchers have constructed the first comprehensive “Metabolic Atlas” of mammalian aging, mapping 12 organs across five distinct life stages in both sexes. The findings, published in Cell Metabolism, offer a radical departure from the “systemic decline” model. Instead of a uniform metabolic collapse, the study reveals a mosaic of organ-specific aging clocks. The most shocking revelation? Contrary to the billion-dollar supplement industry’s central premise, NAD+ levels and the NAD+/NADH ratio remained largely unchanged across most tissues during healthy aging.

The research identifies the thymus as the “canary in the coal mine,” exhibiting the most dramatic metabolic rewiring (50% of metabolites altered) starting as early as adolescence. Conversely, the spleen’s metabolic profile largely stabilizes after early adulthood. The team also discovered a potent new aging biomarker: Hydroxyproline, a breakdown product of collagen, which consistently plummets across 11 of 12 organs, signaling a systemic failure in extracellular matrix turnover. Furthermore, they identified Carglumic acid not just as a waste product, but as a potential driver of aging synthesized by human cells, while reaffirming Alpha-Ketoglutarate (AKG) as a robust signature of youth. This study shifts the focus from “boosting” metabolism indiscriminately to targeting specific organ failures and waste-product accumulation.

Part 2: The Biohacker Analysis

Study Design Specifications

  • Type: In vivo / Multi-organ metabolomic profiling.
  • Subjects: C57BL/6NCrl mice (Note: C57BL/6N strain, not the standard C57BL/6J.
  • Demographics: Male and Female.
  • Organs: Heart, thymus, lungs, liver, pancreas, spleen, kidney, bladder, quadriceps, tongue, brain, plasma.

Lifespan Data

  • Extension: Not a lifespan study. This is an observational atlas.
  • Validation: The study cross-referenced findings with previous datasets, confirming Alpha-Ketoglutarate (AKG) as a youth-associated metabolite previously shown to extend lifespan (~12-15% in prior studies).
  • Driver Identification: Identified Carglumic acid as a pro-aging metabolite; reducing it is a theoretical lifespan extension target, but untried in this paper.

Mechanistic Deep Dive

  • The NAD+ Controversy: The study found no significant decline in NAD+ or the NAD+/NADH ratio in most tissues during healthy aging. This directly contradicts the rationale for indiscriminate precursor supplementation (NR/NMN) in healthy subjects, suggesting that localized flux, rather than total pool availability, may be the bottleneck—or that NAD+ decline is pathological, not intrinsic to aging.
  • Collagen & Extracellular Matrix (ECM): Hydroxyproline levels dropped in 11/12 organs. This indicates a “stiffening” phenotype where collagen degradation slows down, leading to fibrosis and loss of tissue elasticity (the “stiff heart/stiff vessel” phenomenon).
  • Organ-Specific Hierarchy:
    • Thymus: The primary site of metabolic aging. 50% of its metabolome shifts, mostly between 3 and 18 months. This confirms “immune aging” as a primary, early-onset driver.
    • Sexual Dimorphism: Male livers showed increased hydroxyproline (fibrosis risk), whereas females followed the systemic decrease.
  • Network Analysis: Essential fatty acids were identified as critical connectors in the aging metabolic network, suggesting lipid membrane composition is a central, under-appreciated aging node.

Critical Limitations

  • Strain Specificity: The use of C57BL/6N mice is a double-edged sword. While it avoids the NNT mutation of the “J” substrain, it makes comparison with the vast majority of longevity literature (which uses J mice) difficult. The “stable NAD+” finding might be specific to this “healthier” mitochondrial background.
  • Descriptive vs. Functional: The paper establishes correlations (Atlas). It proves AKG predicts youth but does not prove that blocking Carglumic acid reverses aging.
  • Missing Data: No functional assays (e.g., grip strength, cognitive tests) were paired with the metabolic snapshots to correlate specific metabolite levels with functional decline.

Part 3: Actionable Intelligence

The Protocol (Translational Hypotheses)

  • Optimize Collagen Turnover (The Hydroxyproline Protocol):
    • Intervention: Do not just “boost collagen” (peptides). You must enhance collagen turnover (degradation and resynthesis).
    • Tools: Pulsed dosing of proteolytic enzymes (Serrapeptase/Nattokinase) away from food to target fibrotic tissue, combined with Glycine/Proline rich inputs (Bone broth/Hydrolyzed collagen) to fuel resynthesis.
  • Re-evaluate NAD+ Strategies:
    • Pivot: If you are healthy and active, high-dose NR/NMN may be chemically redundant. Focus on NAMPT activation (exercise, circadian fasting) to maintain the flux rather than the pool. Save precursors for stress states (viral infection, sleep deprivation) or known pathology.
  • AKG Stacking:
    • Dosage: Continue/Start Calcium-AKG (Ca-AKG) at ~1g/day (standard human extrapolated dose). This paper reinforces AKG as a fundamental “youth signal” metabolite.

Biomarkers (N=1 Experiments)

  • Serum Hydroxyproline: Track this to assess collagen turnover. A drop suggests fibrotic stagnation.
  • Cystatin C & eGFR: To proxy kidney health, as the kidney and bladder showed distinct metabolic aging signatures.
  • Essential Fatty Acid Panel: specifically Omega-3 index and AA/EPA ratio, as lipid handling was a key network node.

Feasibility & ROI

  • Cost: Low to Moderate. AKG is cheap. Collagen modulation is cheap.
  • ROI: High. Moving away from expensive NAD+ boosters (if healthy) saves ~$100/month. Targeting fibrosis (collagen stiffness) addresses a root cause of hypertension and fragility with low-cost interventions.

Population Applicability

  • Sex-Specific: High. The study emphasizes that male and female livers age differently. Men need to be more aggressive about liver fibrosis prevention (alcohol modulation, fructose reduction) than women based on the hydroxyproline data.

Context:

#2

Gemini: to what extent is the de novo NAD pathway with kynurenine changed with variations in splicing

Variations in splicing change the de novo NAD+ pathway (the kynurenine pathway) to a significant extent, primarily by acting as a “functional switch” that can dampen enzymatic activity, alter tissue-specific localization, or completely abolish the production of NAD+ in favor of other metabolites.

While the liver relies on the canonical, full-length enzymes to maintain systemic NAD+ homeostasis, other tissues (like the brain and immune cells) rely heavily on alternative splicing to fine-tune this pathway. This regulation prevents the toxic accumulation of intermediates (like quinolinic acid) and controls immune tolerance.

The following analysis details the extent of these changes by specific enzyme and functional outcome.

1. The “Gatekeeper” Enzymes: IDO1, IDO2, and TDO2

The entry point of the pathway is the most heavily regulated by splicing. Variations here determine whether tryptophan enters the NAD+ biosynthetic pathway at all or is preserved for serotonin/melatonin synthesis.

Enzyme Splicing Variation Functional Extent of Change
IDO2 Internal Exon Skipping Major Functional Switch (On/Off). IDO2 is a clear example where splicing creates a “functional mosaic.” A common splice variant lacks an internal exon, leading to a catalytic inactive protein. In many human tissues, this variant acts as a dominant “off” switch, rendering IDO2 functionally irrelevant for NAD+ synthesis compared to IDO1.
IDO1 5’ UTR Variants (Class 1 vs 2) Fine-Tuning & Inducibility. Splicing affects the 5’ untranslated region (UTR), which controls how easily the gene is translated in response to stress (e.g., interferon-gamma). While it doesn’t always kill catalytic activity, it changes the “sensitivity” of the pathway, making it hyper-reactive in inflammation (e.g., in immune cells) but stable in other tissues.
TDO2 Tissue-Specific Transcripts Localization Control. Alternative transcripts effectively restrict TDO2 activity to the liver (and specific brain regions). This compartmentalization ensures that systemic tryptophan levels are regulated by the liver without depleting the brain’s tryptophan supply needed for neurotransmitters.

2. The “Bottleneck” Enzyme: QPRT

Quinolinate Phosphoribosyltransferase (QPRT) is the final gatekeeper that commits unstable intermediates to NAD+ synthesis. Splicing here is critical because QPRT prevents the buildup of Quinolinic Acid (QUIN), a potent neurotoxin.

  • Extent of Change: Structural Instability & Activity Loss.
    • Mechanism: QPRT functions as a hexamer (a complex of 6 units). Splicing variants often lack specific exons or have distinct N-termini that disrupt this assembly.
    • Consequence: If a splice variant cannot form the hexamer, the enzyme becomes unstable or inactive. In the brain, a shift toward these inactive splice variants can be disastrous, leading to a “bottleneck” where toxic QUIN accumulates instead of being converted to NAD+, driving neurodegeneration (seen in Alzheimer’s and Huntington’s contexts).

3. Downstream Enzymes: KYNU and HAAO

These enzymes process the intermediates between tryptophan and NAD+.

  • KYNU (Kynureninase):
    • Isoform Switching: Alternative splicing generates multiple isoforms (e.g., isoform a vs. b) with different C-termini.
    • Impact: These variations alter the enzyme’s catalytic efficiency. In cancer cells, specific splice variants are favored to rapidly deplete tryptophan (suppressing the immune system) without necessarily prioritizing NAD+ production.
  • HAAO:
    • Loss of Function: While less characterized for regulatory splicing than IDO, splice variants that induce frameshifts or exon skips lead to congenital NAD+ deficiency. This results in severe developmental defects (malformations of heart, kidney, vertebrae), proving that “correct” splicing is essential for life, not just a fine-tuning mechanism.

Summary of Impact by Context

To answer “to what extent”:

  1. In Homeostasis (Liver): Minimal Extent. The liver expresses the canonical, full-length isoforms to ensure steady production of NAD+ for the whole body. Splicing variations here are rare in health.
  2. In Disease (Cancer): High Extent. Tumors often hijack splicing machinery to produce hyper-active or dysregulated isoforms of IDO1/KYNU. This depletes tryptophan in the microenvironment, shutting down T-cells (immune escape) while fueling the tumor’s own NAD+ needs.
  3. In the Brain: Critical Extent. The brain operates on a “razor’s edge” of splicing. It must balance NAD+ synthesis with neurotoxicity. A shift in splicing (e.g., QPRT inactivation) can instantly flip the pathway from “neuroprotective” (making NAD+) to “neurotoxic” (making Quinolinic Acid).

Next Step

Would you like me to diagram the specific “bottleneck” at the QPRT step to visualize how splicing failures there lead to neurotoxicity vs. NAD+ synthesis?

#3

Not sure why the AI ignored rejuvenating the thymus in its protocol. We have at least some human data that hgh helps here.

#4

There are plenty of human studies on NAD+ vs age and they show that NAD+ levels are essentially the same in young adults and exercise-trained older adults.

Here is a Nature Aging paper (Paywalled :frowning:): Healthy aging and muscle function are positively associated with NAD+ abundance in humans

That’s very encouraging: No significant differences between 20~30 yo vs exercise-trained 65~80 yo.
No need for NR or NMN.

image
image1156×616 96.8 KB

2 Likes
#6

Ok so I plugged the new study in ChatGPT and this is what I got back for anyone curious

I found the actual study you referenced — “A Metabolic Atlas of Mouse Aging” (Pilley, Awad, Latumalea, Kennedy, Lyssiotis, Mullen, et al.) — and here’s how it affects the big picture on NAD and aging: 

:white_check_mark: What the new study actually did
• It quantified metabolites across 12 organs in mice at multiple ages to map how metabolism changes with age. 
• It created organ-specific metabolic aging clocks and identified metabolic predictors of age and aging trajectories. 
• They found distinct metabolic shifts in aging tissues and sex-dependent differences in how metabolites change. 

So this is a massively broad metabolomic dataset — the largest of its kind — that moves aging research past single pathways to a holistic metabolic landscape.

⸻

:white_check_mark: What this study does not show

:pushpin: It is not primarily about NAD⁺ decline — the study doesn’t overturn decades of prior research that NAD⁺ tends to decrease in aging tissues. (The core design is metabolome mapping, not mechanistic NAD biology.) 

:pushpin: It doesn’t claim “NAD⁺ doesn’t decline with age.” The atlas likely documents changes in NAD and related metabolites across tissues, but it does not overturn the overall aging trend seen in prior studies. (If anything, the supplemental data indicate NAD levels change with age — but the pattern is complex.) 

In other words:
:white_check_mark: The atlas adds rich data on how metabolism changes with age across organs.
:x: It doesn’t negate the general observation that NAD⁺ declines with age.

⸻

:white_check_mark: How this study refines our understanding — but doesn’t overturn it

:compass: 1. Aging isn’t uniform across tissues

The atlas shows that metabolites often change in organ-specific ways — some decline sharply, others plateau, and some change non-linearly with age. This hints that:
• NAD changes likely don’t follow a single linear model across all tissues
• Some tissues may maintain NAD better than others
• Metabolic aging signatures are not uniform — they can be sex-dependent too 

This matches broader aging data showing heterogeneity in metabolic aging.

⸻

:dna: 2. NAD decline is contextual, not absolute

The study’s scope strengthens the idea that:
• Some pathways compensate for changes in others
• Redox metabolism and nucleotide metabolism (which includes NAD intermediates) shift with age
• Metabolic clocks integrate many metabolites, not just NAD-centric ones

Basically: NAD is one piece of a larger metabolic aging puzzle. Decline in NAD is real, but the biological context is more complex than “declines everywhere at the same rate.”

⸻

:gear: 3. It reinforces metabolic aging as a network effect

Earlier frameworks treated NAD-decline as a somewhat isolated phenomenon tied to CD38, PARPs, and salvage pathways. This atlas suggests:
• Many metabolite pathways interact
• Aging is best tracked by multi-metabolite signatures, not single variables
• Predictors like alpha-ketoglutarate and hydroxyproline emerged as aging indicators across tissues 

So NAD is part of a broader metabolic shifting landscape, not a lone rate-limiting aging variable.

⸻

:white_check_mark: Implication for human aging and activity

This is important for your original question about NAD levels in extremely active, fit humans:

:white_check_mark: The study supports that metabolic aging is heterogeneous — different tissues and pathways shift at different rates.
:white_check_mark: NAD likely does decline in many tissues with age, but the extent and pattern vary.
:white_check_mark: Lifestyle factors (exercise, low inflammation, low visceral fat) modulate these pathways — potentially preserving some metabolic profiles.

But it does not overturn the fact that NAD declines with age on average, even in active adults — it just shows the story is more nuanced and tissue-dependent.
It also emphasizes that we should think about aging as a network of metabolites and pathways, not just NAD. 

⸻

:pushpin: Updated Bottom Line (Based on the New Paper)

Does this new “Metabolic Atlas of Mouse Aging” change the core conclusion?

:heavy_check_mark: It refines it. Aging changes metabolism in complex, organ-specific ways.
:heavy_check_mark: It contextualizes NAD within a wider metabolic shift, not as a single universal “aging meter.”
✘ It does not nullify the general finding that NAD declines with age.

So:
:white_check_mark: NAD decline with aging — even in healthy, active individuals — remains supported.
:white_check_mark: The new study emphasizes that aging effects vary by organ and interact with many metabolic pathways.

#7

Btw, this is the second new study showing that Hydroxyproline might have much bigger benefits than we knew about.